2. Immunology/Inflammation NF-κB
  3. Interleukin Related NF-κB
  4. MOR-106

MOR-106  (Synonyms: MOR12743; MOR03207)

Cat. No.: HY-P991598 Purity: 97.42%
COA
SDS
Technical Support

MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis.

For research use only. We do not sell to patients.

CAS No. : 2304625-87-2

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

MOR-106 Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target[1][2]

NF-κB

 

IL-17C

 

In Vitro

MOR-106 (0.00001-1 nM, 30 min) potently blocks the interaction of human (IC50 = 59 pM) IL-17C and mouse (IC50 = 55 pM) IL-17C to IL-17RE[1].
MOR-106 (0.0001-1 μg/mL, 30 min) significantly inhibits IL-17C induced activation of NF-κB signaling pathway in NIH3T3 cells[1].
MOR-106 (0.001-1 μg/mL, 48 h) significantly inhibits the expression of DEFB4A and CSF3 induced by IL-17C and TNF-α in human and mouse primary keratinocytes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MOR-106 Related Antibodies

RT-PCR[1]

Cell Line: human and mouse primary keratinocytes
Concentration: 0.001-1 μg/mL
Incubation Time: 48 h
Result: Significantly reduced the levels of DEFB4A and CSF3.
In Vivo

MOR-106 (10 mg/kg, i.p., 3 days before and just before the first injection of IL-23) significantly reduces IL-23-induced skin inflammation in female BALB/c mice[1].
MOR-106 (0.4-50 mg/kg, i.p., 3 days before, at the start, and 4 days after the first application of MC903) effectively alleviates MC903 induced atopic dermatitis and atopic eczema in female BALB/c mice[1][2].
MOR-106 (3 and 30 mg/kg, i.p., twice weekly, for 6 weeks) alleviates spontaneous atopic dermatitis in Flaky tail mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: IL-23 (1 μg, for 4 consecutive days) injeceted female BALB/c mice (8 weeks)[1]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection (i.p.), 3 days before and just before the first injection of IL-23
Result: Significantly reduced ear swelling and epidermal thickening.
Reduced the expression of inflammatory factors such as IL-17A, IL-22, IL-1β, LCN2, S100A8 and S100A9.
Animal Model: Topical administration of 2 nM MC903 (HY-10001) for 5 days to female BALB/c mice (8 weeks)[1][2]
Dosage: 0.4, 2, 10 and 50 mg/kg
Administration: Intraperitoneal injection (i.p.), 3 days before, at the start, and 4 days after the first application of MC903
Result: Dose dependently reduced ear swelling and epidermal thickening.
Reduced TSLP, IL-33, and CCL17 levels.
Significantly reduced skin infiltration of T cells, eosinophils, and neutrophils.
Animal Model: Flaky tail mice on a congenic C57BL/6J background[1]
Dosage: 3 and 30 mg/kg
Administration: Intraperitoneal injection (i.p.), twice weekly for 6 weeks
Result: Significantly reduced skin inflammation score.
Reduced the number of mast cells and serum IgE levels.
Reduced the expression of IL-4, IL-17A, CCL17 and IFN-γ.
Clinical Trial
Gene ID

27189  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

144.02 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

N/A
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
  • Immobilized Human IL-17c, His Tag can bind MOR-106. The EC50 for this effect is 7.102 ng/mL.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

MOR-106 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MOR-1062304625-87-2MOR12743 MOR03207MOR106MOR 106MOR 12743MOR-12743MOR03207MOR 03207MOR-03207Interleukin RelatedNF-κBILNuclear factor-κBNuclear factor-kappaBIL-17Cpsoriasisatopic dermatitisInflammationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MOR-106
Cat. No.:
HY-P991598
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.